BioCryst Pharmaceuticals reports Q3 ORLADEYO net revenue of $159.1 million and operating profit of $29.6 million
Reuters
Nov 03
BioCryst Pharmaceuticals reports Q3 ORLADEYO net revenue of $159.1 million and operating profit of $29.6 million
BioCryst Pharmaceuticals Inc. reported third quarter 2025 financial results with ORLADEYO net revenue of $159.1 million, a 37 percent increase year-over-year. The company posted an operating profit of $29.6 million, up 285 percent from the previous year, and a non-GAAP operating profit of $51.7 million, a 107 percent year-over-year rise. BioCryst raised its full-year 2025 ORLADEYO revenue guidance to between $590 million and $600 million and lowered its full-year non-GAAP operating expense guidance to between $430 million and $440 million. The company completed the sale of its European ORLADEYO business, using the proceeds to retire all remaining Pharmakon term debt. BioCryst also signed a definitive agreement to acquire Astria Therapeutics, with the transaction expected to close in the first quarter of 2026. Research and development expenses for the third quarter increased to $44.6 million, primarily due to the advancement of BCX17725 and pre-clinical program activities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9566972-en) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.